FundingWatcher
Home / Startups / Top health care startups / Health care startups that raised Series B / Health care startups that raised Series B in China

Health care startups that raised Series B in China

Updated 16 Nov 2026

Reset
Health care startups that raised Series B in China
One-time CSV
  • 664 funded companies, 468 with a website
  • Last round, amount, date, total raised and investors
  • CRM-ready CSV, 18 columns
  • Download right after payment
With founder contacts
Compiled to order
  • The full startup CSV, plus founders and executives
  • Up to 2 founders or CEOs per company, compiled to order
  • Name, job title and LinkedIn URL where found
  • Verified direct email per person
  • Startup CSV at once, contacts CSV by mail within 24 hours
Download right after paymentFree 10-row sampleSecure checkout by Stripe

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

startups-health-care--series-b~china-500a.csv664 rows × 18 columns
CompanyCityLast roundAmountDate
Huasaiboman Medical Cell BiologyQingdao ShiSeries B$30.0M2026-11-09
EnjosimShanghaiSeries B$30.1M2026-11-02
Hyperway PharmChengduSeries B$14.9M2026-10-15
Bluesail SurgicalShanghaiSeries B$104.5M2026-09-23
MedefaZhuhaiSeries B$14.9M2026-09-02
Yuce BiotechnologySuzhouSeries B$7.4M2026-08-31
MileBot RoboticsShenzhenSeries B$14.9M2026-08-26
Leadinno Medical ValleyBeijingSeries B$29.7M2026-08-17

8 rows of the CSV in 5 of its 18 columns.

664
Startups
$16.6B
Total raised
106
Funded in the last 12 months
$1.8B
Raised in the last 12 months

Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.

Newest rounds

30 of 664
30 rows
Company What they do Sector City Last round Amount Date Total raised Investors Employees Founded
Huasaiboman Medical Cell Biology Huasaiboman Medical Cell Biology provides new cell therapy technologies and solutions as a biotechnology company. Biotech Qingdao Shi Series B $30.0M 2026-11-09 $30.0M ASBV 11 to 50 2019
Enjosim Enjosim researches, manufactures, and sells self-delivery systems for biomacromolecule pharmaceuticals. Biotech Shanghai Series B $30.1M 2026-11-02 $30.1M Luminous Ventures (former Lightspeed China Partners), Jiayuan Capital 51 to 100 2021
Hyperway Pharm Hyperway Pharm conducts pharmaceutical research, development, and production. Health care Chengdu Series B $14.9M 2026-10-15 $56.8M Si Chuan Venture Capital, Chengdu High-tech Ceyuan Capital, Huaige Capital +1 51 to 100 2019
Bluesail Surgical Bluesail Surgical develops surgical instruments for cardiovascular treatments. Biotech Shanghai Series B $104.5M 2026-09-23 $245.4M Huagai Capital, Linkong Private Equity Fund Management, Linqu County High-Tech Industrial Investment 101 to 250 2020
Medefa Medefa uses synthetic biology to mass-produce novel PHA biomaterials. Biotech Zhuhai Series B $14.9M 2026-09-02 $16.3M Motianshi Touzi, Taiping Innovation 11 to 50 2019
Yuce Biotechnology Yuce Biotechnology focuses on the industrialization of single-molecule immunodiagnostic technologies. Biotech Suzhou Series B $7.4M 2026-08-31 $22.4M Puhua Capital, Zhengxuan Investment, BioTrack Capital +2 101 to 250 2019
MileBot Robotics MileBot Robotics develops robots for medical and healthcare applications. Artificial intelligence Shenzhen Series B $14.9M 2026-08-26 $14.9M Lenovo Capital and Incubator Group (LCIG), Share Capital, Shangyuan Capital 101 to 250 2016
Leadinno Medical Valley Leadinno Medical Valley produces medical devices that regulate neurological functions. Health care Beijing Series B $29.7M 2026-08-17 $90.3M Fortune Venture Capital, Cowin Capital, Taiyu Investment +2 10,001 or more 2016
Hongxin Biology Hongxin Biology develops mRNA drugs and delivers nucleic acid therapeutics to patients. Biotech Shenzhen Series B $14.0M 2026-08-13 $14.0M Haiyuan Capital, Shenzhen Small & Medium Enterprises Credit Financing Guarantee Group 11 to 50 2021
Layerwave Bio Layerwave Bio develops diagnostic instrument reagents and biomedical research instruments. Biotech Daxing Series B $13.8M 2026-07-28 $13.8M IDG Capital, Addor Capital, Hotung Venture Capital 51 to 100 2020
MindRank AI MindRank AI develops artificial intelligence platforms to discover and develop small molecule drugs. Artificial intelligence Shanghai Series B $52.0M 2026-07-08 $101.0M Green Pine Capital Partners, Huagai Capital, Sherpa Healthcare Partners +1 11 to 50 2020
Sonosemi Medical Sonosemi Medical provides medical devices for vascular interventional diagnosis and treatment. Health care Shenzhen Series B $27.3M 2026-07-08 $27.3M Eight Roads Ventures, Co-Stone Venture Capital, Guangzhou Yuexiu Industrial Investment Fund +1 101 to 250 2020
X-MAGTECH X-MAGTECH provides a technology platform for measuring extremely weak magnetic fields. Health care Haidian Series B $14.8M 2026-06-04 $43.5M IDG Capital, CAS Star, Everest Venture Capital +1 101 to 250 2018
HemaCell HemaCell develops cell therapies that regenerate hematopoietic lineages in vitro through stem cell reprogramming. Biotech Suzhou Series B $14.8M 2026-06-02 $62.0M Northern Light Venture Capital, CDH Investments, CMB International Capital Corporation 1 to 10 2021
Menovex Menovex develops and markets laser medical devices for treating oral and skin conditions. Health care Shenzhen Series B $14.8M 2026-06-02 $14.8M Infinity Equity 2019
Bivision Bivision researches and develops targeted radiopharmaceuticals for therapy. Biotech Shanghai Series B $58.8M 2026-05-18 $100.9M Gaorong Capital, Kaitai Capital, Lichen Capital 11 to 50 2021
Hypershell Hypershell develops wearable exoskeletons that support walking, hiking, and cycling. Artificial intelligence Shenzhen Series B $50.0M 2026-05-18 $121.2M MiraclePlus, Decent Capital, Vitalbridge Capital 101 to 250 2021
Novamab Novamab researches and develops new nanobodies. Biotech Shanghai Series B $43.9M 2026-04-24 $97.8M Qiming Venture Partners, Taiyu Investment, Fuho Capital +1 51 to 100 2017
AccuPulse AccuPulse develops pulsed electric field ablation generators and catheters. Health care Suzhou Series B $14.5M 2026-03-13 $72.5M BioVenture, Shanghai Biomedical Industrial Equity Investment Fund, Med-Fine Capital +1 11 to 50 2020
CSR Biotech CSR Biotech provides cell imaging and data processing services for biological research. Biotech Haidian Series B $45.0M 2026-03-10 $45.0M Qiming Venture Partners 51 to 100 2019
Tingsheng Technology Tingsheng Technology develops intracardiac ultrasound (ICE) products. Health care Nanjing Series B $13.9M 2026-03-05 $52.8M Qiming Venture Partners, Taiyu Investment, Tao Capital +2 2017
RoboCT RoboCT develops exoskeleton robots that help patients with lower-body motor dysfunction learn to walk. Artificial intelligence Yuhang Series B $14.5M 2026-03-04 $47.3M Fortune Venture Capital, Poly Capital, Pappas Capital 51 to 100 2017
Findcure Findcure develops anti-cancer medications through drug discovery and development. Biotech Daxing Series B $14.5M 2026-02-14 $14.5M Hecheng Capital, Renxi Fund, Yishang Huicheng Investments 11 to 50 2019
Transcend Vivoscope Transcend Vivoscope is a biotechnology company that offers advanced microscopy imaging products and solutions. Biotech Haidian Series B $14.5M 2026-02-10 $14.5M China Capital Management, Zefu Innovation, Guangzhou Tongxin Science and Technology Innovation Fund 11 to 50 2016
Alioth Alioth develops and applies technical products for pharmaceutical process technology. Biotech Shanghai Series B $14.4M 2026-01-15 $54.7M Matrix Partners China, Legend Capital 51 to 100 2021
Yuewei Medical Yuewei Medical develops interventional medical devices for cardiac surgery. Health care Beijing Series B $14.3M 2026-01-12 $28.4M IDG Capital, South China Venture Capital, Yuanhui Chuangyi +1 2019
Anlong Bio Anlong Bio researches and develops nucleic acid drugs, including gene therapy, RNA drugs, and gene editing. Biotech Beijing Series B $14.3M 2026-01-07 $14.3M TaiKun Fund 51 to 100 2019
D3 Bio D3 Bio develops and registers medicines as a biotechnology company. Biotech Wuxi Shi Series B $108.0M 2025-12-09 $370.0M Matrix Partners China, Boyu Capital, Medicxi 1 to 10 2020
Rigen Biotech Rigen Biotech provides molecular diagnosis of thyroid tumors. Biotech Minhang Series B $14.1M 2025-11-28 $29.8M BioTrack Capital, Boyuan Capital, Guotai Junan Innovation Investment +1 101 to 250 2017
Jingwei Shida Jingwei Shida researches, develops, and supplies optoelectronic medical equipment. Health care Wuhan Series B $14.1M 2025-11-21 $14.1M Northern Light Venture Capital, SND Ventures Group, Insight Capital 11 to 50 2014

Table 1. Health care startups that raised Series B in China: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 664.

Largest rounds

Last 12 months
10 rows
# Company What they do Sector City Last round Amount Date Total raised Investors Employees Founded
1 D3 Bio D3 Bio develops and registers medicines as a biotechnology company. Biotech Wuxi Shi Series B $108.0M 2025-12-09 $370.0M Matrix Partners China, Boyu Capital, Medicxi 1 to 10 2020
2 Bluesail Surgical Bluesail Surgical develops surgical instruments for cardiovascular treatments. Biotech Shanghai Series B $104.5M 2026-09-23 $245.4M Huagai Capital, Linkong Private Equity Fund Management, Linqu County High-Tech Industrial Investment 101 to 250 2020
3 Bivision Bivision researches and develops targeted radiopharmaceuticals for therapy. Biotech Shanghai Series B $58.8M 2026-05-18 $100.9M Gaorong Capital, Kaitai Capital, Lichen Capital 11 to 50 2021
4 MindRank AI MindRank AI develops artificial intelligence platforms to discover and develop small molecule drugs. Artificial intelligence Shanghai Series B $52.0M 2026-07-08 $101.0M Green Pine Capital Partners, Huagai Capital, Sherpa Healthcare Partners +1 11 to 50 2020
5 Hypershell Hypershell develops wearable exoskeletons that support walking, hiking, and cycling. Artificial intelligence Shenzhen Series B $50.0M 2026-05-18 $121.2M MiraclePlus, Decent Capital, Vitalbridge Capital 101 to 250 2021
6 CSR Biotech CSR Biotech provides cell imaging and data processing services for biological research. Biotech Haidian Series B $45.0M 2026-03-10 $45.0M Qiming Venture Partners 51 to 100 2019
7 Novamab Novamab researches and develops new nanobodies. Biotech Shanghai Series B $43.9M 2026-04-24 $97.8M Qiming Venture Partners, Taiyu Investment, Fuho Capital +1 51 to 100 2017
8 Enjosim Enjosim researches, manufactures, and sells self-delivery systems for biomacromolecule pharmaceuticals. Biotech Shanghai Series B $30.1M 2026-11-02 $30.1M Luminous Ventures (former Lightspeed China Partners), Jiayuan Capital 51 to 100 2021
9 Huasaiboman Medical Cell Biology Huasaiboman Medical Cell Biology provides new cell therapy technologies and solutions as a biotechnology company. Biotech Qingdao Shi Series B $30.0M 2026-11-09 $30.0M ASBV 11 to 50 2019
10 Leadinno Medical Valley Leadinno Medical Valley produces medical devices that regulate neurological functions. Health care Beijing Series B $29.7M 2026-08-17 $90.3M Fortune Venture Capital, Cowin Capital, Taiyu Investment +2 10,001 or more 2016

Table 2. Health care startups that raised Series B in China: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most active investors

By companies backed
#InvestorTypeLocation CompaniesShare Funded, 12 monthsLatest
1 Qiming Venture Partners Venture capital firm Shanghai, China 14 2% 3 Novamab, CSR Biotech, Tingsheng Technology
2 IDG Capital Private equity firm Beijing, China 11 2% 3 Layerwave Bio, X-MAGTECH, Yuewei Medical
3 Matrix Partners China Venture capital firm Beijing, China 9 1% 2 Alioth, D3 Bio
4 Legend Capital Venture capital firm Beijing, China 8 1% 1 Alioth
5 Puhua Capital Venture capital firm Hangzhou, China 6 1% 1 Yuce Biotechnology
6 CDH Investments Private equity firm Kowloon City, Hong Kong 6 1% 1 HemaCell
7 Shenzhen Capital Group Venture capital firm Nanshan, China 6 1%
8 BioTrack Capital Venture capital firm Shanghai, China 5 1% 2 Yuce Biotechnology, Rigen Biotech
9 Lenovo Capital and Incubator Group (LCIG) Venture capital firm Beijing, China 5 1% 1 MileBot Robotics
10 Taiyu Investment Venture capital firm Beijing, China 5 1% 3 Leadinno Medical Valley, Novamab, Tingsheng Technology
11 Fortune Venture Capital Venture capital firm Shenzhen, China 5 1% 2 Leadinno Medical Valley, RoboCT
12 Northern Light Venture Capital Venture capital firm Beijing, China 5 1% 2 HemaCell, Jingwei Shida
13 Sinovation Ventures Venture capital firm Beijing, China 5 1%
14 Sherpa Healthcare Partners Venture capital firm Beijing, China 4 1% 1 MindRank AI
15 Green Pine Capital Partners Venture capital firm Shenzhen, China 4 1% 1 MindRank AI

Table 3. Health care startups that raised Series B in China: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Sectors

SectorsCompaniesShareTotal raised
Biotech 261 39% $7.9B
Software 86 13% $1.7B
Hardware 44 7% $500.1M
Artificial intelligence 34 5% $968.0M
Commerce 25 4% $2.0B
Education 12 2% $109.8M
Fintech 7 1% $117.3M
Energy 3 0%
Cybersecurity 1 0%

Table 4. Health care startups that raised Series B in China by sector. Source: FundingWatcher. Data as of 16 November 2026.

Funding stage

Funding stageCompaniesShareMedian last round
Series B 664 100% $14.4M

Table 5. Health care startups that raised Series B in China by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Cities

CitiesCompaniesShare
Shanghai 106 16%
Beijing 93 14%
Hangzhou 55 8%
Shenzhen 53 8%
Suzhou 45 7%
Guangzhou 28 4%
Nanjing 26 4%
Haidian 25 4%
Chengdu 17 3%
Wuhan 14 2%
Daxing 11 2%
Minhang 11 2%

Table 6. Health care startups that raised Series B in China by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.

Rounds by month

Rounds by monthCompaniesShareRaised
November 2026 6 6% $90.0M
October 2026 5 5% $145.3M
September 2026 8 8% $311.3M
August 2026 6 6% $80.5M
July 2026 7 7% $207.2M
June 2026 7 7% $44.3M
May 2026 7 7% $179.2M
April 2026 6 6% $75.6M
March 2026 12 11% $166.5M
February 2026 11 10% $85.9M
January 2026 12 11% $130.1M
December 2025 13 12% $230.5M
November 2025 6 6% $42.3M

Table 7. Health care startups that raised Series B in China: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most recent round by year

Most recent round by yearCompaniesShareRaised
2026 87 13% $1.5B
2025 77 12% $921.4M
2024 52 8% $732.9M
2023 67 10% $974.4M
2022 66 10% $1.5B
2021 56 8% $2.5B

Table 8. Health care startups that raised Series B in China by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Founding year

Founding yearCompaniesShare
2023 or later 1 0%
2020 to 2022 76 12%
2015 to 2019 288 44%
2010 to 2014 178 27%
Before 2010 115 17%

Table 9. Health care startups that raised Series B in China by founding year. Source: FundingWatcher. Data as of 16 November 2026.

Team size

Team sizeCompaniesShare
1 to 10 62 10%
11 to 50 174 29%
51 to 100 131 22%
101 to 250 120 20%
251 to 500 60 10%
501 to 1,000 22 4%
1,001 to 5,000 19 3%
5,001 to 10,000 3 1%
10,001 or more 2 0%

Table 10. Health care startups that raised Series B in China by headcount. Source: FundingWatcher. Data as of 16 November 2026.

Method

Sources, fields and exclusions of both files: Method.

Questions

How many health care startups in China whose last round is Series B are on the list?
664, in the file dated 16 November 2026. 106 of them closed their most recent round in the last 12 months.
What does the CSV contain?
One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
How much does the list cost?
$29 one-time for all 664 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $349.
What arrives after payment?
At once: the CSV download link, on the page after payment and by mail.
Can I see rows before buying?
The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
How current is the data?
The file is dated 16 November 2026. The download link serves the current file each time it is opened.

Health care startups that raised Series B in China: 664 rows, CSV, $29 one-time.

At once: the CSV download link, on the page after payment and by mail.

Columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.

With founder contacts: $349 one-time. List CSV right after payment; up to 2 verified founder or CEO emails per company compiled to order within 24 hours.

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

Health care at other stages in China

Other sectors that raised Series B in China

Cite: FundingWatcher, 664 health care companies in China whose most recent round is Series B, 16 November 2026. https://fundingwatcher.com/startups/health-care/series-b/china-500a/